Iterum submits NDA for oral sulopenem; Q1 net loss narrows to $7.1M, cash runway into 2025

Iterum Therapeutics plc

NDA resubmitted in April 2024 for oral sulopenem; FDA action expected early Q4 2024.
Cash, equivalents & short-term investments $18.2M at March 31, 2024; ATM raised $7.2M in Q1.
Net loss $7.1M in Q1 2024 vs $9.9M in Q1 2023; non-GAAP net loss $5.8M vs $7.4M.
R&D expenses fell to $4.0M from $6.4M as REASSURE trial enrollment completed in October 2023.
Cash runway extended into 2025, including through expected PDUFA date in early Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Iterum Therapeutics plc reported first quarter ended March 31, 2024 results: net income $7.1 million.

Period: first quarter ended March 31, 2024
Net income: $7.1 million
Result: reported results

Exact text from the filing

iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-24-058190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.